Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06822920
Recruiting Observational

Post-Market Clinical Investigation Plan - Collagen Dura Membranes (DM & DMO)

NCT06822920 · tracked via the Priya Life Science USA tracker
Sponsor
Collagen Matrix
Phase
Observational
Started
2025-01-03
Last updated
2025-02-12

Condition(s) studied

Repair of Dura Mater

Study summary

Monitoring the Use of Collagen Dura Membrane in the Post-market phase

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with a dural defect requiring repair with a dural substitute. Exclusion Criteria: * There are no subject restrictions for the study other than patients with known allergy to bovine collagen products as specified in the contraindications of the Instructions for Use.

Primary outcome measure(s)

  • Measurement of the occurrence of adverse event requiring surgical intervention — 6-9 months

Trial sites (1)

FacilityCityRegionStatus
Medical Collagen of Wisconsin Milwaukee Wisconsin Recruiting

More Collagen Matrix trials in the USA

Clinical Investigation Plan - Post-market Clinical Follow-up Study Collagen Dura Membrane - Suturable Starting soon
OssiMend BA in Posterolateral Instrumented Lumbar Fusion Recruiting
Post-market Clinical Investigation Plan: Collagen Dura Regeneration Membrane - Repair (DMR) Starting soon
Post-Market Clinical Investigation Plan- Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus) Recruiting

Other trials for the same condition

Clinical Investigation Plan - Post-market Clinical Follow-up Study Collagen Dura Membrane - Suturable Starting soon
Post-market Clinical Investigation Plan: Collagen Dura Regeneration Membrane - Repair (DMR) Starting soon
Post-Market Clinical Investigation Plan- Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06822920 on ClinicalTrials.gov ↗ ← All trials in the USA